Peer-reviewed research, video abstracts, and curated reading.
Published work, curated research, and the landmark studies that shape modern kidney and metabolic nutrition science.
Featured video abstract
A visual summary of my Nutrients publication on hyperphosphatemia in kidney failure.
Source: encyclopedia.pub/video/1810
Selected publications
Nutrients
Hyperphosphatemia in Kidney Failure: Pathophysiology, Challenges, and Critical Role of Phosphorus Management
Author · May 2025
Journal of the American Society of Nephrology (JASN)
Role of Tenapanor in the Management of Hyperphosphatemia
Author · October 2025
In preparation — expected November 2026
The Hidden Dangers of Hyperphosphatemia in Health and Kidney Disease: Etiology, Complications, and Interventions
Lead author · 2026
In preparation — expected March 2027
Lupus Nephritis: Molecular Pathogenesis, Biomarkers, and Emerging Targeted Therapies in Precision Medicine
Author · 2027
Speaking engagements
Institution, date, and topic for scheduled and past talks.
- Past
Kidney Failure. Patient Interaction
UT Southwestern Medical Center
A talk for students and faculty on the lived patient experience of kidney failure — my own story, and practical guidance on how clinicians can approach treating patients with kidney disease with more empathy and effectiveness.
Speaker topics
Each talk is delivered with cited slides, a written takeaway sheet, and an optional patient Q&A panel.
Hyperphosphatemia in 2026 — From Binders to Tenapanor
A practice-oriented review of phosphate management built on my Nutrients and JASN publications. Suitable for nephrology grand rounds, dietitian CEU sessions, and pharma medical-affairs briefings.
The Patient-Researcher Voice — Rebuilding Trust in CKD Education
How peer-reviewed science and lived patient experience together produce better adherence, better outcomes, and stronger institutional credibility.
Plant-Dominant Low-Protein Diets (PLADO) for Real Patients
Operationalizing the evidence behind plant-forward CKD nutrition without losing patients to restriction fatigue.
CKM Syndrome — Nutrition at the Heart-Kidney-Metabolic Intersection
Implementing the 2023 AHA CKM staging in everyday clinical and community education programs.
Curated research
Foundational trials and clinical guidelines in kidney and metabolic care.
Clinical guidelines
3 readingsKDIGO 2024 Guideline
Evaluation and Management of Chronic Kidney Disease
The global reference standard for CKD care — essential reading for any patient or clinician.
KDIGO
2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Foundational for IgA nephropathy, lupus nephritis, and other immune-mediated kidney disease.
KDIGO
2024 Clinical Practice Guideline for the Management of Lupus Nephritis
The new lupus nephritis playbook — multi-target induction, voclosporin/belimumab add-on, and steroid minimization.
Kidney-protective therapies
6 readingsNEJM
Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD)
Landmark trial reshaping kidney-protective therapy across diabetic and non-diabetic CKD.
NEJM
Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY)
Confirms SGLT2 benefit across a broad CKD population — practice-changing evidence.
NEJM
Finerenone in CKD and Type 2 Diabetes (FIDELIO-DKD)
A new pillar in cardiorenal protection that every CKD patient should know about.
European Heart Journal
Finerenone in CKD and Type 2 Diabetes — Pooled FIDELIO-DKD & FIGARO-DKD (FIDELITY)
Pooled analysis confirming that finerenone and SGLT2 inhibitors are additive — patients benefit from both pillars, not one or the other.
NEJM
Semaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease (FLOW)
First trial proving a GLP-1 receptor agonist reduces major kidney events and cardiovascular death in CKD — reshapes the CKD treatment algorithm.
NEJM
Tirzepatide for Obesity and Heart Failure with Preserved Ejection Fraction (SUMMIT)
Cardiometabolic precedent for tirzepatide that increasingly informs how we manage CKM-syndrome patients.
Glomerular & lupus disease
4 readingsLancet
Sparsentan in Patients with IgA Nephropathy (PROTECT)
Dual endothelin/angiotensin antagonism delivers a meaningful proteinuria reduction beyond ACE/ARB in IgAN — central to the new KDIGO IgAN pathway.
NEJM
Atrasentan in Patients with IgA Nephropathy (ALIGN)
Selective endothelin-A antagonism with a clean safety signal — another emerging option for high-risk IgAN.
NEJM
Voclosporin for Lupus Nephritis (AURORA 1)
First calcineurin inhibitor with FDA approval for active lupus nephritis — pivotal for the modern triple-therapy paradigm.
NEJM
Belimumab plus Standard Therapy for Lupus Nephritis (BLISS-LN)
Adding belimumab to standard induction improves renal response — supports KDIGO 2024 add-on therapy guidance.
Nutrition & dietary patterns
3 readingsCJASN
Healthy Dietary Patterns and Risk of Mortality and ESRD in CKD: A Meta-Analysis
Real-world evidence that plant-forward, Mediterranean-style eating slows CKD progression and reduces mortality.
Nutrients
Plant-Dominant Low-Protein Diet (PLADO) for Conservative Management of CKD
The original Kalantar-Zadeh framework paper — a flexible, plant-forward alternative to rigid low-protein prescriptions.
Kidney International
Dietary Phosphorus Intake and Mortality in Moderate CKD
Real-world evidence that higher dietary phosphorus — driven largely by inorganic phosphate additives — tracks with mortality and vascular harm in CKD.
Turn this research into your plan
Want this evidence translated to your labs and life?
The Nutritional Blueprint is a 90-minute deep dive that maps the trials above (DAPA-CKD, EMPA-KIDNEY, FLOW, KDIGO 2024) onto your diagnosis, medications, and food preferences — with a written plan you can hand your nephrologist.